Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Phase I/II, Non-randomized, Open Label, Multicenter Study to Determine Safety and Efficacy of Nilotinib in a Population With Steroid-refractory/or Steroid-dependent cGVHD.

NCT01810718 is registered in ClinicalTrials.gov with Gruppo Italiano Trapianto di Midollo Osseo as lead sponsor.

NCT NCT01810718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01810718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Phase I/II, Non-randomized, Open Label, Multicenter Study to Determine Safety and Efficacy of Nilotinib in a Population With Steroid-refractory/or Steroid-dependent cGVHD.
Lead sponsor
Gruppo Italiano Trapianto di Midollo Osseo
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2011
Completion date
March 31, 2016
Enrollment
22 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease